Fig. 5

Overall survival and disease-specific survival curves for methotrexate-associated T-cell lymphoproliferative disorder of angioimmunoblastic T-cell lymphoma type compared to angioimmunoblastic T-cell lymphoma. Patients with methotrexate-associated T-cell lymphoproliferative disorder of angioimmunoblastic T-cell lymphoma type (MTX-AITL) had superior overall survival curve and progression-free survival curve, though the differences from angioimmunoblastic T-cell lymphoma (AITL) were not significant (a, b). Overall survival and progression-free survival curves for the patients of the two groups who are 60 years or older were also compared. The survival curves showed the same trend (c, d)